AbbVie presents ABBV-466 Crohn’s disease data
The company reported higher endoscopic remission rates with its dual-targeting therapy than with either anti-IL-23 or anti-α4β7 monotherapy in moderate to severe Crohn’s disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.